Free Trial
NASDAQ:ELTX

Elicio Therapeutics Q1 2026 Earnings Report

Elicio Therapeutics logo
$10.75 -0.86 (-7.41%)
As of 11:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Elicio Therapeutics EPS Results

Actual EPS
-$0.65
Consensus EPS
-$0.49
Beat/Miss
Missed by -$0.16
One Year Ago EPS
N/A

Elicio Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Elicio Therapeutics Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Monday, May 11, 2026
Conference Call Time
4:00PM ET

Elicio Therapeutics Earnings Headlines

ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
See More Elicio Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elicio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elicio Therapeutics and other key companies, straight to your email.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

View Elicio Therapeutics Profile